Epigenetic analysis of sporadic and Lynchassociated ovarian cancers reveals histologyspecific patterns of DNA methylation

Epigenetics

Volumn 9, Issue 12, 2015, Pages 1577-1587

  Niskakoski, Anni ^a   Kaur, Sippy ^a   Staff, Synnöve ^b,c   Renkonen Sinisalo, Laura ^d   Lassus, Heini ^d   Järvinen, Heikki J ^d   Mecklin, Jukka Pekka ^e,f   Bützow, Ralf ^d   Peltomäki, Päivi ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^c TAMPERE UNIVERSITY HOSPITAL   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

DNA methylation; Epigenetics; HOXA9; Lynch syndrome; MS MLPA ovarian cancer; RSK4; SPARC

Indexed keywords

OSTEONECTIN; PEPTIDES AND PROTEINS; PROTEIN CABLES1; PROTEIN MIR34B; PROTEIN PROM1; PROTEIN RSK4; TRANSCRIPTION FACTOR HOXA10; TRANSCRIPTION FACTOR HOXA9; UNCLASSIFIED DRUG; TUMOR MARKER;

ARTICLE; CARCINOGENESIS; CONTROLLED STUDY; CPG ISLAND; DISEASE ASSOCIATION; DNA METHYLATION; EPIGENETICS; GENE EXPRESSION PROFILING; GENE SEQUENCE; GENETIC ANALYSIS; HISTOLOGY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; OVARY CANCER; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; COMPLICATION; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HEREDITARY NONPOLYPOSIS COLORECTAL CANCER; NEOPLASM; OVARIAN NEOPLASMS; PATHOLOGY; PROMOTER REGION; REFERENCE VALUE; TUMOR CELL LINE;

CARCINOMA, ENDOMETRIOID; CELL LINE, TUMOR; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; CPG ISLANDS; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OVARIAN NEOPLASMS; PROMOTER REGIONS, GENETIC; REFERENCE VALUES; TUMOR MARKERS, BIOLOGICAL;

EID: 84922031816     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/15592294.2014.983374     Document Type: Article

References (45)

1. Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61:183-203; PMID:21521830; http://dx. doi.org/10.3322/caac.20113.
2. Lynch HT, Casey MJ, Snyder CL, Bewtra C, Lynch JF, Butts M, Godwin AK. Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Mol Oncol 2009; 3:97-137; PMID: 19383374; http://dx.doi.org/10.1016/j.molonc. 2009.02.004
3. Aarnio M, Sankila R, Pukkala E, Salovaara R, Aaltonen LA, de la Chapelle A, Peltomaki P, Mecklin JP, Jarvinen HJ. Cancer risk in mutation carriers of DNA-mismatch- repair genes. Int J Cancer 1999; 81:214-8; PMID:10188721; http://dx.doi.org/10.1002/(SICI) 1097-0215(19990412)81:2%3c214::AID-IJC8%3e3. 0.CO;2-L.
4. Engel C, Loeffler M, Steinke V, Rahner N, Holinski- Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel Doeberitz M, Goecke TO, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol 2012; 30:4409-4415; PMID:23091106; http://dx.doi.org/10.1200/ JCO.2012.43.2278
5. Shih I, Kurman RJ. Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis. Am J Pathol 2004; 164:1511-8; PMID:15111296; http://dx.doi.org/10.1016/S0002- 9440(10)63708-X
6. Cho KR, Shih I. Ovarian cancer. Annu Rev Pathol 2009; 4:287-313; PMID:18842102; http://dx.doi.org/ 10.1146/annurev.pathol.4.110807.092246
7. Soslow RA. Histologic subtypes of ovarian carcinoma: An overview. Int J Gynecol Pathol 2008; 27:161-74; PMID:18317227
8. Prat J. Ovarian carcinomas: Five distinct diseases with different origins, genetic alterations, and clinicopathological features. Virchows Arch 2012; 460:237-249; PMID:22322322; http://dx.doi.org/10.1007/s00428- 012-1203-5
9. Kuhn E, Kurman RJ, Shih IM. Ovarian cancer is an imported disease: Fact or fiction? Curr Obstet Gynecol Rep 2012; 1:1-9; PMID:22506137; http://dx.doi.org/ 10.1007/s13669-011-0004-1
10. Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis 2010; 31:27-36; PMID:19752007; http://dx.doi.org/10.1093/carcin/bgp220
11. Kolbe DL, DeLoia JA, Porter-Gill P, Strange M, Petrykowska HM, Guirguis A, Krivak TC, Brody LC, Elnitski L. Differential analysis of ovarian and endometrial cancers identifies a methylator phenotype. PLoS One 2012; 7:e32941; PMID:22403726; http://dx.doi.org/ 10.1371/journal.pone.0032941
12. Houshdaran S, Hawley S, Palmer C, Campan M, Olsen MN, Ventura AP, Knudsen BS, Drescher CW, Urban ND, Brown PO, et al. DNA methylation profiles of ovarian epithelial carcinoma tumors and cell lines. PLoS One 2010; 5:e9359; PMID:20179752; http://dx.doi.org/10.1371/journal.pone.0009359
13. Watts GS, Futscher BW, Holtan N, Degeest K, Domann FE, Rose SL. DNA methylation changes in ovarian cancer are cumulative with disease progression and identify tumor stage. BMC Med Genomics 2008; 1:47-8794-1-47; PMID:18237448; http://dx.doi.org/ 10.1186/1755-8794-1-47
14. Maradeo ME, Cairns P. Translational application of epigenetic alterations: Ovarian cancer as a model. FEBS Lett 2011; 585:2112-20; PMID:21402071; http://dx. doi.org/10.1016/j.febslet.2011.03.016
15. Widschwendter M, Jones A, Teschendorff AE. Epigenetics makes its mark on women-specific cancers-an opportunity to redefine oncological approaches? Gynecol Oncol 2013; 128:134-43; PMID:23036354; http://dx.doi.org/10.1016/j.ygyno.2012.09.027
16. Balch C, Fang F, Matei DE, Huang TH, Nephew KP. Minireview: Epigenetic changes in ovarian cancer. Endocrinology 2009; 150:4003-11; PMID:19574400; http://dx.doi.org/10.1210/en.2009-0404
17. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474:609-15; PMID:21720365; http://dx.doi.org/ 10.1038/nature10166
18. Niskakoski A, Kaur S, Renkonen-Sinisalo L, Lassus H, Jarvinen HJ, Mecklin JP, Butzow R, Peltomaki P. Distinct molecular profiles in lynch syndrome-associated and sporadic ovarian carcinomas. Int J Cancer 2013; 133:2596-608; PMID:23716351
19. Dewdney SB, Rimel BJ, Thaker PH, Thompson DM, Jr, Schmidt A, Huettner P, Mutch DG, Gao F, Goodfellow PJ. Aberrant methylation of the X-linked ribosomal S6 kinase RPS6KA6 (RSK4) in endometrial cancers. Clin Cancer Res 2011; 17:2120-9; PMID:21372219; http://dx.doi.org/10.1158/1078- 0432.CCR-10-2668
20. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133C ovarian cancer cells. Oncogene 2009; 28:209-18; PMID:18836486; http:// dx.doi.org/10.1038/onc.2008.374
21. Wu Y, Halverson G, Basir Z, Strawn E, Yan P, Guo SW. Aberrant methylation at HOXA10 may be responsible for its aberrant expression in the endometrium of patients with endometriosis. Am J Obstet Gynecol 2005; 193:371-80; PMID:16098858; http://dx.doi. org/10.1016/j.ajog.2005.01.034
22. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken- Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, et al. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 2010; 16:1119-28; PMID:20145172; http://dx. doi.org/10.1158/1078-0432.CCR-09-2642
23. Myers AP, Corson LB, Rossant J, Baker JC. Characterization of mouse Rsk4 as an inhibitor of fibroblast growth factor-RAS-extracellular signal-regulated kinase signaling. Mol Cell Biol 2004; 24:4255-66; PMID:15121846; http://dx.doi.org/10.1128/ MCB.24.10.4255-4266.2004
24. Bornstein P, Sage EH. Matricellular proteins: Extracellular modulators of cell function. Curr Opin Cell Biol 2002; 14:608-16; PMID:12231357; http://dx.doi.org/ 10.1016/S0955-0674(02)00361-7
25. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med 2005; 11:531-7; PMID:15821746; http://dx.doi.org/10.1038/nm1230
26. Sakamoto H, Friel AM, Wood AW, Guo L, Ilic A, Seiden MV, Chung DC, Lynch MP, Serikawa T, Munro E, et al. Mechanisms of cables 1 gene inactivation in human ovarian cancer development. Cancer Biol Ther 2008; 7:180-8; PMID:18059193; http://dx. doi.org/10.4161/cbt.7.2.5253
27. Kawano Y, Kypta R. Secreted antagonists of the wnt signalling pathway. J Cell Sci 2003; 116:2627-34; PMID:12775774; http://dx.doi.org/10.1242/jcs.00623
28. Sellar GC, Watt KP, Rabiasz GJ, Stronach EA, Li L, Miller EP, Massie CE, Miller J, Contreras-Moreira B, Scott D, et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat Genet 2003; 34:337-43; PMID:12819783; http://dx.doi.org/10.1038/ng1183
29. Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in epithelial ovarian cancer is associated with low insulin-like growth factor- II expression and favorable prognosis. Cancer Res 2007; 67:10117-22; PMID:17974952; http://dx.doi. org/10.1158/0008-5472.CAN-07-2544
30. Socha MJ, Said N, Dai Y, Kwong J, Ramalingam P, Trieu V, Desai N, Mok SC, Motamed K. Aberrant promoter methylation of SPARC in ovarian cancer. Neoplasia 2009; 11:126-35; PMID:19177197
31. Fiegl H, Windbichler G, Mueller-Holzner E, Goebel G, Lechner M, Jacobs IJ, Widschwendter M. HOXA11 DNA methylation-a novel prognostic biomarker in ovarian cancer. Int J Cancer 2008; 123:725-9; PMID:18478570; http://dx.doi.org/10.1002/ijc.23563
32. Montavon C, Gloss BS, Warton K, Barton CA, Statham AL, Scurry JP, Tabor B, Nguyen TV, Qu W, Samimi G, et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol 2012; 124:582-8; PMID:22115852; http://dx.doi.org/10.1016/j. ygyno.2011.11.026
33. Chen H, Ye F, Zhang J, Lu W, Cheng Q, Xie X. Loss of OPCML expression and the correlation with CpG island methylation and LOH in ovarian serous carcinoma. Eur J Gynaecol Oncol 2007; 28:464-7; PMID:18179137
34. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104:1924-30; PMID:16134181; http://dx.doi.org/10.1002/cncr.21397
35. He X, He L, Hannon GJ. The guardian's little helper: microRNAs in the p53 tumor suppressor network. Cancer Res 2007; 67:11099-101; PMID:18056431; http://dx.doi.org/10.1158/0008-5472.CAN-07-2672
36. Agostini M, Knight RA. miR-34: From bench to bedside. Oncotarget 2014; 5:872-81; PMID:24657911
37. Gal-Yam EN, Saito Y, Egger G, Jones PA. Cancer epigenetics: Modifications, screening, and therapy. Annu Rev Med 2008; 59:267-80; PMID:17937590; http:// dx.doi.org/10.1146/annurev.med.59.061606.095816
38. Sun Y, Cao S, Yang M, Wu S, Wang Z, Lin X, Song X, Liao DJ. Basic anatomy and tumor biology of the RPS6KA6 gene that encodes the p90 ribosomal S6 kinase-4. Oncogene 2013; 32:1794-810; PMID:22614021; 10.1038/onc.2012.200.
39. Chen J, Wang M, Xi B, Xue J, He D, Zhang J, Zhao Y. SPARC is a key regulator of proliferation, apoptosis and invasion in human ovarian cancer. PLoS One 2012; 7:e42413; PMID:22879971; http://dx.doi.org/ 10.1371/journal.pone.0042413
40. Ko SY, Barengo N, Ladanyi A, Lee JS, Marini F, Lengyel E, Naora H. HOXA9 promotes ovarian cancer growth by stimulating cancer-associated fibroblasts. J Clin Invest 2012; 122:3603-17; PMID:22945634; http://dx.doi.org/10.1172/JCI62229
41. Kalari S, Pfeifer GP. Identification of driver and passenger DNA methylation in cancer by epigenomic analysis. Adv Genet 2010; 70:277-308; PMID:20920752; http://dx.doi.org/10.1016/B978-0-12-380866-0. 60010-1
42. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Yamada H, Yamamoto R, Sakuragi N, Enokida H, Verma M, Dahiya R. WT1 and WT1-AS genes are inactivated by promoter methylation in ovarian clear cell adenocarcinoma. Cancer 2005; 104:1924-1930; PMID: 16134181; http://dx.doi.org/10.1002/cncr.21397
43. Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Joensuu EI, Jarvinen HJ, Mecklin JP, Aarnio M, Peltomaki PT. Differential cancer predisposition in lynch syndrome: Insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 2008; 29:1351-9; PMID:18550572; http://dx.doi. org/10.1093/carcin/bgn133
44. Derks S, Bosch LJ, Niessen HE, Moerkerk PT, van den Bosch SM, Carvalho B, Mongera S, Voncken JW, Meijer GA, de Bruine AP, et al. Promoter CpG island hypermethylation- and H3K9me3 and H3K27me3- mediated epigenetic silencing targets the deleted in colon cancer (DCC) gene in colorectal carcinogenesis without affecting neighboring genes on chromosomal region 18q21. Carcinogenesis 2009; 30:1041-8; PMID:19329758; 10.1093/carcin/bgp073.
45. Nymark P, Lindholm PM, Korpela MV, Lahti L, Ruosaari S, Kaski S, Hollmen J, Anttila S, Kinnula VL, Knuutila S. Gene expression profiles in asbestosexposed epithelial and mesothelial lung cell lines. BMC Genomics 2007; 8:62; PMID:17331233; http://dx.doi. org/10.1186/1471-2164-8-62